Business & Finance
Regenxbio reports quarter ended 30 September 2020 financial results
5 November 2020 -

Regenxbio Inc (Nasdaq: RGNX), a clinical-stage biotechnology company, has reported its financial results for the quarter ended 30 September 2020, it was reported on Wednesday.

The company reported revenues of USD98.9m for the three months ended 30 September 2020 against USD14.7m for the same period of 2019.

The firm posted net income of USD8.8m or USD0.23 diluted net income per share for the three months ended 30 September 2020, compared to a net loss of USD34.6m or USD0.94 net loss per diluted share for the year-ago period.

Kenneth T Mills, president and chief executive officer of REGENXBIO, said, 'We have made several important advancements in our clinical pipeline during the third quarter of 2020, with continued focus on execution during the COVID-19 pandemic. I'm pleased that two Phase II trials are underway for the treatment of wet AMD and diabetic retinopathy using the suprachoroidal approach for the delivery of RGX-314. In addition, we have expanded our RGX-121 program for patients with MPS II to gain additional insight into the potential treatment effects of this one-time gene therapy candidate in more patients, and we have dosed additional patients in the second cohort of the ongoing Phase I/II trial. I look forward to providing additional updates on all of our clinical programs in 2021, as we continue to focus on the significant unmet medical needs in both large indications and rare diseases.'